Preferred Label : somatostatin;

MeSH definition : A 14-amino acid peptide named for its ability to inhibit pituitary GROWTH HORMONE release, also called somatotropin release-inhibiting factor. It is expressed in the central and peripheral nervous systems, the gut, and other organs. SRIF can also inhibit the release of THYROID-STIMULATING HORMONE; PROLACTIN; INSULIN; and GLUCAGON besides acting as a neurotransmitter and neuromodulator. In a number of species including humans, there is an additional form of somatostatin, SRIF-28 with a 14-amino acid extension at the N-terminal.;

MeSH synonym : srih-14; somatotropin release-inhibiting factor; somatotropin release-inhibiting hormone; somatostatin, cyclic; somatostatin-14; somatotropin release inhibiting hormone; somatostatin 14; somatotropin release inhibiting factor; cyclic somatostatin;

MeSH hyponym : somatofalk; stilamin;

Registry Number MeSH : 51110-01-1;

Wikipedia link : https://en.wikipedia.org/wiki/Somatostatin;

Is substance : O;

Details


Main resources

You can consult :

A 14-amino acid peptide named for its ability to inhibit pituitary GROWTH HORMONE release, also called somatotropin release-inhibiting factor. It is expressed in the central and peripheral nervous systems, the gut, and other organs. SRIF can also inhibit the release of THYROID-STIMULATING HORMONE; PROLACTIN; INSULIN; and GLUCAGON besides acting as a neurotransmitter and neuromodulator. In a number of species including humans, there is an additional form of somatostatin, SRIF-28 with a 14-amino acid extension at the N-terminal.

https://www.has-sante.fr/portail/jcms/c_2908487/fr/signifor
2019
true
false
France
French
evaluation of the transparency committee
acromegaly
pituitary acth hypersecretion
pasireotide
orphan drug production
pasireotide
adult
somatostatin
injections, intramuscular
aged
insurance, health, reimbursement
treatment outcome
risk management
product surveillance, postmarketing

---
https://www.has-sante.fr/portail/jcms/c_2839029/fr/signifor
2018
false
false
France
French
evaluation of the transparency committee
acromegaly
pituitary acth hypersecretion
pasireotide
pasireotide
orphan drug production
pasireotide
adult
somatostatin
injections, intramuscular
aged
insurance, health, reimbursement
treatment outcome
risk management
product surveillance, postmarketing

---
http://www.has-sante.fr/portail/jcms/c_2625989/fr/somatuline-lp
2016
false
France
French
gastro-enteropancreatic neuroendocrine tumor
lanreotide acetate
lanreotide
injections
Delayed-Action preparations
peptides, cyclic
somatostatin
lanreotide
antineoplastic agents
treatment outcome
insurance, health, reimbursement
evaluation of the transparency committee
intestinal neoplasms
pancreatic neoplasms
stomach neoplasms
neuroendocrine tumors

---
http://www.has-sante.fr/portail/jcms/c_2586912/fr/somatuline-lp
http://www.has-sante.fr/portail/jcms/c_1019676/somatuline-lp
2015
false
France
French
Thyrotroph Pituitary Neuroendocrine Tumor
lanreotide
injections
Delayed-Action preparations
peptides, cyclic
somatostatin
lanreotide
acromegaly
antineoplastic agents
carcinoid tumor
treatment outcome
insurance, health, reimbursement
pituitary neoplasms
evaluation of the transparency committee

---
http://www.has-sante.fr/portail/jcms/c_2034331/fr/signifor
http://www.has-sante.fr/portail/jcms/c_2034331/fr/signifor-pasireotide-analogue-de-la-somatostatine
2015
false
France
French
evaluation of the transparency committee
acromegaly
guidelines for drug use
pasireotide
pasireotide
orphan drug production
pasireotide
adult
somatostatin
injections, intramuscular
aged
insurance, health, reimbursement
treatment outcome
risk management
product surveillance, postmarketing

---
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailTwo.php?lang=fr&linkID=SBD00269
2013
false
false
false
Canada
Pasireotide 0.3mg/mL injection solution (product)
Pasireotide 0.6mg/mL injection solution (product)
Pasireotide 0.9mg/mL injection solution (product)
pasireotide
pasireotide
drug information
somatostatin
somatostatin

---
http://www.cochrane.org/fr/CD008370
2012
false
true
false
United Kingdom
France
postoperative complications
treatment outcome
review of literature
french abstract
somatostatin
pancreas

---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=67953372
2012
France
summary of product characteristics
package leaflet
somatostatin
powders

---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=60272948
2012
France
summary of product characteristics
package leaflet
somatostatin
powders

---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=63548469
2012
France
summary of product characteristics
package leaflet
powders
somatostatin

---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=66600871
2012
France
summary of product characteristics
package leaflet
injections
somatostatin

---
http://www.cochrane.org/fr/CD000193
2012
United Kingdom
France
French
french abstract
meta-analysis
esophageal and gastric varices
bleeding esophageal varices
gastrointestinal hemorrhage
somatostatin
acute disease
somatostatin

---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=64929761
2012
France
summary of product characteristics
package leaflet
somatostatin

---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=69472124
2012
France
summary of product characteristics
package leaflet
somatostatin

---
http://www.has-sante.fr/portail/jcms/c_1320044/signifor-pasireotide-analogue-de-la-somatostatine
http://www.has-sante.fr/portail/jcms/c_1320024/signifor-18072012-synthese
http://www.has-sante.fr/portail/upload/docs/application/pdf/2012-08/signifor_18072012_ct12258.pdf
http://www.has-sante.fr/portail/jcms/c_1284805/signifor
2012
false
France
French
corticosteroid therapy
pasireotide
pasireotide
pasireotide
somatostatin
pituitary acth hypersecretion
drug approval
evaluation of the transparency committee
guidelines for drug use
orphan drug production
insurance, health, reimbursement
adult
injections, subcutaneous
aged
treatment outcome
clinical trials, phase iii as topic
hydrocortisone
risk management

---
https://www.ema.europa.eu/medicines/human/EPAR/Signifor
2012
United Kingdom
English
French
summary of product characteristics
package leaflet
drug evaluation
syndication feed
pasireotide
pasireotide
pasireotide
drug approval
treatment outcome
injections, subcutaneous
orphan drug production
somatostatin
adult
aged
drug interactions
pregnancy
breast feeding
fertility
receptors, somatostatin
somatostatin receptor 5
drug evaluation, preclinical
pituitary acth hypersecretion
self administration

---
https://www.ema.europa.eu/medicines/human/EPAR/NeoSpect
2010
United Kingdom
French
English
syndication feed
injections, intravenous
technetium Tc 99m depreotide
technetium Tc 99m depreotide
organotechnetium compounds
somatostatin
lung neoplasms
organotechnetium compounds
somatostatin
somatostatin
radiopharmaceuticals
technetium (99mtc) depreotide
drug evaluation
summary of product characteristics
package leaflet

---
http://www.meddispar.fr/medicaments/3572889
2008
France
French
Delayed-Action preparations
somatostatin
peptides, cyclic
injections
drug prescriptions
legislation, drug
lanreotide
lanreotide
drug information

---
https://www.cadth.ca/sites/default/files/cdr/complete/cdr_complete_Somatuline-Autogel_July-19-2007_f.pdf
2007
Canada
French
acromegaly
antineoplastic agents
somatostatin
peptides, cyclic
lanreotide
lanreotide
drug evaluation

---
http://www.john-libbey-eurotext.fr/fr/revues/medecine/hpg/e-docs/00/02/4A/15/resume.md?type=text.html
2000
France
French
journal article
liver neoplasms
liver neoplasms
neuroendocrine tumors
somatostatin
neuroendocrine tumors
interferons
octreotide
pancreatic neoplasms
digestive system neoplasms

---
https://www.jle.com/fr/revues/medecine/met/e-docs/00/02/BF/A9/resume.md
1997
France
French
somatostatin
endocrine gland neoplasms
journal article

---
Nous contacter.
01/11/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.